Dermira (NASDAQ: DERM) reported Q3 EPS of ($1.06), $0.24 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $11.5 million versus the consensus estimate of $11.22 million.

“The third quarter was marked by notable progress on key commercial, clinical and regulatory initiatives as we build a dynamic medical dermatology company,” said Tom Wiggans, chairman and chief executive officer at Dermira. “As we look ahead to 2020, we have a number of attractive investment opportunities, including two programs of significant value in QBREXZA and lebrikizumab. In the context of our business and what we anticipate will be an evolving financial environment, we are evaluating our capital allocation strategy and overall investment levels. As a result of this ongoing process, we expect to leverage our progress and experience with the QBREXZA launch, and the strong foundation we have established, to target our investment in a manner that significantly reduces our commercial expenses while continuing to drive growth for the brand.”

For earnings history and earnings-related data on Dermira (DERM) click here.